Botulinum Toxin Induced Atrophy: An Uncharted Territory

Botulinum neurotoxins (BoNTs) produce local chemo-denervation by cleaving soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) proteins. Botulinum neurotoxins are therapeutically indicated in several neurological disorders and have been in use for three decades. The long-ter...

Full description

Bibliographic Details
Main Authors: Mehri Salari, Soumya Sharma, Mandar S. Jog
Format: Article
Language:English
Published: MDPI AG 2018-08-01
Series:Toxins
Subjects:
Online Access:http://www.mdpi.com/2072-6651/10/8/313
id doaj-456341aaa5404c2ab0d720adc2e3e10e
record_format Article
spelling doaj-456341aaa5404c2ab0d720adc2e3e10e2020-11-25T02:45:12ZengMDPI AGToxins2072-66512018-08-0110831310.3390/toxins10080313toxins10080313Botulinum Toxin Induced Atrophy: An Uncharted TerritoryMehri Salari0Soumya Sharma1Mandar S. Jog2Department of Clinical Neurological Sciences, London Health Sciences Centre, Western University, 339 Windermere Road, A10-026, London, ON N6A 5A5, CanadaDepartment of Clinical Neurological Sciences, London Health Sciences Centre, Western University, 339 Windermere Road, A10-026, London, ON N6A 5A5, CanadaDepartment of Clinical Neurological Sciences, London Health Sciences Centre, Western University, 339 Windermere Road, A10-026, London, ON N6A 5A5, CanadaBotulinum neurotoxins (BoNTs) produce local chemo-denervation by cleaving soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) proteins. Botulinum neurotoxins are therapeutically indicated in several neurological disorders and have been in use for three decades. The long-term efficacy, safety, and side effects of BoNTs have been well documented in the literature. However, the development of muscle atrophy following chronic exposure to BoNTs has not received sufficient attention. Muscle atrophy is not only cosmetically distressing, but also has an impact on future injections. An extensive literature search was conducted on atrophy and mechanisms of atrophy. Five hundred and four relevant articles in the English language were reviewed. This review revealed the surprising lack of documentation of atrophy within the literature. In addition, as demonstrated in this review, the mechanisms and the clinical factors that may lead to atrophy have also been poorly studied. However, even with this limited information it is possible to indicate factors that could modify the clinical approach to botulinum toxin injections. This review highlights the need for further study of atrophy following BoNT injections.http://www.mdpi.com/2072-6651/10/8/313botulinum toxinatrophySNARE
collection DOAJ
language English
format Article
sources DOAJ
author Mehri Salari
Soumya Sharma
Mandar S. Jog
spellingShingle Mehri Salari
Soumya Sharma
Mandar S. Jog
Botulinum Toxin Induced Atrophy: An Uncharted Territory
Toxins
botulinum toxin
atrophy
SNARE
author_facet Mehri Salari
Soumya Sharma
Mandar S. Jog
author_sort Mehri Salari
title Botulinum Toxin Induced Atrophy: An Uncharted Territory
title_short Botulinum Toxin Induced Atrophy: An Uncharted Territory
title_full Botulinum Toxin Induced Atrophy: An Uncharted Territory
title_fullStr Botulinum Toxin Induced Atrophy: An Uncharted Territory
title_full_unstemmed Botulinum Toxin Induced Atrophy: An Uncharted Territory
title_sort botulinum toxin induced atrophy: an uncharted territory
publisher MDPI AG
series Toxins
issn 2072-6651
publishDate 2018-08-01
description Botulinum neurotoxins (BoNTs) produce local chemo-denervation by cleaving soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) proteins. Botulinum neurotoxins are therapeutically indicated in several neurological disorders and have been in use for three decades. The long-term efficacy, safety, and side effects of BoNTs have been well documented in the literature. However, the development of muscle atrophy following chronic exposure to BoNTs has not received sufficient attention. Muscle atrophy is not only cosmetically distressing, but also has an impact on future injections. An extensive literature search was conducted on atrophy and mechanisms of atrophy. Five hundred and four relevant articles in the English language were reviewed. This review revealed the surprising lack of documentation of atrophy within the literature. In addition, as demonstrated in this review, the mechanisms and the clinical factors that may lead to atrophy have also been poorly studied. However, even with this limited information it is possible to indicate factors that could modify the clinical approach to botulinum toxin injections. This review highlights the need for further study of atrophy following BoNT injections.
topic botulinum toxin
atrophy
SNARE
url http://www.mdpi.com/2072-6651/10/8/313
work_keys_str_mv AT mehrisalari botulinumtoxininducedatrophyanunchartedterritory
AT soumyasharma botulinumtoxininducedatrophyanunchartedterritory
AT mandarsjog botulinumtoxininducedatrophyanunchartedterritory
_version_ 1724763569368596480